查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918103

抗肥胖药物市场－2026-2031年预测

Anti-Obesity Drug Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计抗肥胖药物市场将从 2025 年的 408.98 亿美元成长到 2031 年的 1,163.81 亿美元，维持 19.04% 的复合年增长率。

由于全球肥胖症及其相关健康问题日益严重，抗肥胖药物市场预计将保持稳定成长。这些药物透过抑制食慾和释放儿茶酚胺等作用机制，为体重管理和维持永续健康提供了有医学依据的途径。人口结构、生活方式和监管因素的综合影响推动了市场扩张，这些因素凸显了有效治疗方案的重要性。

市场的主要驱动因素是全球各年龄层肥胖症盛行率的不断上升，其中儿童肥胖症的惊人增长尤为突出。这一普遍存在的健康问题正显着扩大需要医疗干预的患者群体。肥胖症与多种严重健康后果密切相关，进一步刺激了对肥胖药物的需求。肥胖是多种慢性疾病的重要危险因素，包括第2型糖尿病和各种癌症，也是全球过早死亡的主要原因之一。肥胖与这些危及生命的合併症之间的直接关联，有力地证明了抗肥胖药物治疗的必要性。

现代生活方式也是市场成长的关键驱动因素。长时间久坐工作（尤其是在企业环境中）、加工食品的摄取、不规则的睡眠以及慢性压力等因素，都造成了促进肥胖的环境。数位科技在日常生活中的普及化进一步加剧了这些久坐习惯。这些生活方式的集体改变已经形成了一个可持续的肥胖人群群体，他们需要药物辅助进行体重管理。

政府和机构的措施正在积极塑造市场格局。国际卫生组织和各国卫生署正在实施反肥胖宣传宣传活动和技术框架，并专注于预防，尤其是在儿童群体中。这些公共卫生措施透过教育大众了解与体重相关的健康风险，并将肥胖定位为一种需要医疗干预的疾病，从而创造了有利于反肥胖治疗的环境。

北美已成为重要的区域市场，这得益于其高肥胖率和完善的法规结构。该地区已获得美国食品药物管理局 (FDA)核准的多种长期体重管理药物，为临床医生提供了丰富的治疗选择。大型製药公司的存在，加上先进的技术基础设施和大规模的研发活动，进一步巩固了北美在抗肥胖治疗领域药物引进和创新方面的主导地位。

该市场蕴藏着巨大的成长机会，尤其是在开发疗效和安全性更高的先进疗法方面。全球因肥胖导致的大量死亡凸显了开发更有效药物干预措施的迫切性。然而，市场成长受到一些限制因素的限制，例如政府对药物核准和使用的严格监管。其他挑战包括体重管理服务的使用率低，以及基于体重指数（BMI）和合併症等因素限制某些患者群体获得药物的处方限制。

在竞争激烈的市场环境中，像 Currax Pharmaceuticals 和 GlaxoSmithKline 这样的专业製药公司销售核准的产品，例如 Contrave® 和 Alli®。这些公司专注于个人化治疗方案和宣传宣传活动，旨在解决肥胖的多种生理和行为问题，这反映了医学界对肥胖的理解和治疗方法日益成熟。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 依作用机转分類的抗肥胖药物市场

  • 介绍
  • 週边作用药物
  • 中枢促效剂

第六章：以药物类型分類的抗肥胖药物市场

  • 介绍
  • 处方药
  • 非处方药

第七章 依给药途径分類的抗肥胖药物市场

  • 介绍
  • 口服
  • 注射

第八章：以最终用户分類的抗肥胖药物市场

  • 介绍
  • 成人
  • 儿童和青少年

第九章 各地区抗肥胖药物市场

  • 介绍
  • 北美洲
    • 透过作用机制
    • 按类型
    • 透过行政途径
    • 最终用户
    • 按国家/地区
      • 我们
      • 加拿大
      • 墨西哥
  • 南美洲
    • 透过作用机制
    • 按类型
    • 透过行政途径
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 透过作用机制
    • 按类型
    • 透过行政途径
    • 最终用户
    • 按国家/地区
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 透过作用机制
    • 按类型
    • 透过行政途径
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 以色列
      • 其他的
  • 亚太地区
    • 透过作用机制
    • 按类型
    • 透过行政途径
    • 最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 泰国
      • 台湾
      • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章 公司简介

  • Currax Pharmaceuticals LLC
  • GlaxoSmithKline PLC
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Eli Lilly and Company
  • VIVUS LLC
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • Rhythm Pharmaceuticals Inc
  • Amgen Inc

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615573

The anti-obesity drug market, sustaining a 19.04% CAGR, is anticipated to reach USD 116.381 billion in 2031 from USD 40.898 billion in 2025.

The anti-obesity drug market is positioned for steady growth, propelled by the escalating global prevalence of obesity and its associated health burdens. These pharmaceutical interventions, which function through mechanisms such as appetite suppression and catecholamine release, offer a medically-supported pathway for weight management and sustainable health. The market's expansion is driven by a confluence of demographic, lifestyle, and regulatory factors that underscore the critical need for effective therapeutic solutions.

A primary market driver is the increasing global prevalence of obesity across all age groups, including a concerning rise in childhood obesity. This widespread health issue creates a substantial and growing patient population in need of medical intervention. The demand for anti-obesity medications is further amplified by the serious adverse health effects strongly correlated with obesity. The condition is a significant risk factor for multiple chronic diseases, including type 2 diabetes and various forms of cancer, positioning it as a major contributor to premature mortality worldwide. This direct link to life-threatening comorbidities underscores the therapeutic necessity of anti-obesity pharmacotherapy.

Modern lifestyle patterns represent another significant contributor to market growth. Factors such as prolonged sedentary behavior, particularly in corporate environments, consumption of processed foods, irregular sleep schedules, and chronic stress have created environmental conditions conducive to obesity. The pervasive integration of digital technology into daily life further compounds these sedentary habits. These collective lifestyle shifts have established a sustained demographic base requiring pharmaceutical support for weight management.

Governmental and institutional initiatives are actively shaping the market landscape. International health organizations and national health departments are implementing awareness campaigns and technical frameworks aimed at combating obesity, particularly focusing on protective measures for children. These public health efforts serve to educate populations about weight-related health risks and legitimize obesity as a condition requiring medical management, thereby fostering a more receptive environment for anti-obesity treatments.

North America emerges as the dominant regional market, a status reinforced by high obesity rates and a progressive regulatory framework. The region benefits from multiple FDA approvals for weight management medications designated for long-term use, providing clinicians with a range of therapeutic options. The presence of major pharmaceutical companies, combined with advanced technological infrastructure and substantial research and development activities, further consolidates North America's leadership position in both adoption and innovation within the anti-obesity drug sector.

The market presents significant opportunities for development, particularly through the creation of advanced therapeutic agents that offer improved efficacy and safety profiles. The substantial global mortality attributed to obesity highlights the urgent need for more effective pharmaceutical interventions. However, market growth is tempered by certain restraining factors, including stringent government regulations governing drug approval and usage. Additional challenges include low utilization rates of weight management services and prescribing limitations that restrict use to specific patient populations based on Body Mass Index and comorbidities.

The competitive landscape features specialized pharmaceutical companies such as Currax Pharmaceuticals and GlaxoSmithKline, which market approved products like Contrave(R) and Alli(R). These players are increasingly focusing on personalized treatment approaches and public awareness campaigns that address the varied physiological and behavioral aspects of obesity, reflecting a maturation in how the condition is understood and treated within the medical community.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Anti-Obesity Drugs Market Segmentation:

  • By Mechanism of Action
  • Peripherally Acting Drugs
  • Centrally Acting Drugs
  • By Drug Type
  • Prescription Drugs
  • OTC Drugs
  • By Mode of Administration
  • Oral
  • Injectable
  • By End-User
  • Adults
  • Children & Youngsters
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. ANTI-OBESITY DRUGS MARKET BY MECHANISM OF ACTION

  • 5.1. Introduction
  • 5.2. Peripherally Acting Drugs
  • 5.3. Centrally Acting Drugs

6. ANTI-OBESITY DRUGS MARKET BY DRUG TYPE

  • 6.1. Introduction
  • 6.2. Prescription Drugs
  • 6.3. OTC Drugs

7. ANTI-OBESITY DRUGS MARKET BY MODE OF ADMINISTRATION

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Inectable

8. ANTI-OBESITY DRUGS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Children & Youngsters

9. ANTI-OBESITY DRUGS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Mechanism of Action
    • 9.2.2. By Type
    • 9.2.3. By Mode of Administration
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Mechanism of Action
    • 9.3.2. By Type
    • 9.3.3. By Mode of Administration
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Mechanism of Action
    • 9.4.2. By Type
    • 9.4.3. By Mode of Administration
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. France
      • 9.4.5.3. United Kingdom
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Mechanism of Action
    • 9.5.2. By Type
    • 9.5.3. By Mode of Administration
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Israel
      • 9.5.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Mechanism of Action
    • 9.6.2. By Type
    • 9.6.3. By Mode of Administration
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. India
      • 9.6.5.3. Japan
      • 9.6.5.4. South Korea
      • 9.6.5.5. Indonesia
      • 9.6.5.6. Thailand
      • 9.6.5.7. Taiwan
      • 9.6.5.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Currax Pharmaceuticals LLC
  • 11.2. GlaxoSmithKline PLC
  • 11.3. Novo Nordisk A/S
  • 11.4. Pfizer Inc.
  • 11.5. Eli Lilly and Company
  • 11.6. VIVUS LLC
  • 11.7. Boehringer Ingelheim International GmbH
  • 11.8. AstraZeneca plc
  • 11.9. Rhythm Pharmaceuticals Inc
  • 11.10. Amgen Inc

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations